Cara Therapeutics, Inc. (CARA)
Largest Insider Buys in Sector
CARA Stock Price History Chart
CARA Stock Performance
About Cara Therapeutics, Inc.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing …
Insider Activity of Cara Therapeutics, Inc.
Over the last 12 months, insiders at Cara Therapeutics, Inc. have bought $0 and sold $42,686 worth of Cara Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cara Therapeutics, Inc. have bought $0 and sold $1.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000,000 shares for transaction amount of $18.19M was made by RHO Ventures VI LP (10 percent owner) on 2017‑03‑31.
List of Insider Buy and Sell Transactions, Cara Therapeutics, Inc.
| 2024-11-04 | Sale | PRESIDENT AND CEO | 3,668 0.0066% | $0.29 | $1,064 | +0.07% | ||
| 2024-08-01 | Sale | PRESIDENT AND CEO | 4,149 0.0075% | $0.35 | $1,452 | -15.02% | ||
| 2024-05-02 | Sale | PRESIDENT AND CEO | 3,936 0.007% | $0.75 | $2,952 | -57.58% | ||
| 2024-04-05 | Sale | SEC'Y; CHIEF COMPLIANCE & G.C. | 2,753 0.0048% | $0.83 | $2,285 | -60.98% | ||
| 2024-04-05 | Sale | CHIEF MEDICAL OFFICER | 2,753 0.0048% | $0.83 | $2,285 | -60.98% | ||
| 2024-02-29 | Sale | PRESIDENT AND CEO | 5,834 0.0115% | $0.89 | $5,192 | -58.46% | ||
| 2024-02-29 | Sale | SEC'Y; CHIEF COMPLIANCE & G.C. | 3,293 0.0065% | $0.89 | $2,931 | -58.46% | ||
| 2024-02-29 | Sale | CHIEF MEDICAL OFFICER | 3,293 0.0065% | $0.89 | $2,931 | -58.46% | ||
| 2024-02-08 | Sale | PRESIDENT AND CEO | 35,575 0.0607% | $0.53 | $18,855 | -29.47% | ||
| 2024-02-01 | Sale | PRESIDENT AND CEO | 4,981 0.0088% | $0.55 | $2,740 | -34.05% | ||
| 2023-11-02 | Sale | President and CEO | 3,796 0.0072% | $1.22 | $4,631 | -44.50% | ||
| 2023-08-03 | Sale | President and CEO | 4,307 0.0077% | $3.07 | $13,222 | -72.76% | ||
| 2023-06-23 | Sale | Chief Scientific Off,SVP-R&D | 2,993 0.0056% | $3.51 | $10,505 | -72.46% | ||
| 2023-06-23 | Sale | Sec'y; Chief Compliance & G.C. | 2,483 0.0046% | $3.51 | $8,715 | -72.46% | ||
| 2023-06-23 | Sale | Chief Medical Officer | 2,723 0.0051% | $3.51 | $9,558 | -72.46% | ||
| 2023-05-05 | Sale | President and CEO | 3,869 0.0072% | $4.40 | $17,024 | -71.98% | ||
| 2023-04-04 | Sale | Chief Scientific Off,SVP-R&D | 2,733 0.0053% | $4.91 | $13,419 | -66.14% | ||
| 2023-04-04 | Sale | Sec'y; Chief Compliance & G.C. | 2,481 0.0048% | $4.91 | $12,182 | -66.14% | ||
| 2023-04-04 | Sale | Chief Medical Officer | 2,481 0.0048% | $4.91 | $12,182 | -66.14% | ||
| 2023-03-03 | Sale | President and CEO | 5,987 0.0105% | $9.71 | $58,134 | -76.65% |
Insider Historical Profitability
| RHO Ventures VI LP | 10 percent owner | 3568057 6.5045% | $0.46 | 4 | 0 | +18.29% |
| ALTA BIOPHARMA PARTNERS III LP | 10 percent owner | 1753447 3.1965% | $0.46 | 1 | 0 | +7.74% |
| Schoell Josef | Chief Financial Officer | 28000 0.051% | $0.46 | 1 | 1 | <0.0001% |
| VOGELBAUM MARTIN | director | 20160 0.0368% | $0.46 | 3 | 2 | +32.73% |
| Stauffer Joseph William | Chief Medical Officer | 2000 0.0036% | $0.46 | 1 | 1 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $3.11M | 6.26 | 3.42M | -3.74% | -$120,934.44 | <0.0001 | |
| The Vanguard Group | $2.26M | 4.54 | 2.48M | -5.69% | -$136,326.14 | <0.0001 | |
| Disciplined Growth Investors Inc Mn | $1.65M | 3.32 | 1.82M | +0.16% | +$2,691.78 | 0.03 | |
| Chescapmanager Llc | $1.55M | 3.11 | 1.7M | -2.85% | -$45,501.82 | 0.26 | |
| Farallon Capital | $1.42M | 2.85 | 1.56M | 0% | +$0 | 0.01 |